Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi

NAVS Naphthalan for Treatment of Oral Mucosal Diseases – A Pilot Study (CROSBI ID 214184)

Prilog u časopisu | izvorni znanstveni rad | međunarodna recenzija

Andabak Rogulj, Ana ; Brkić, Denis ; Alajbeg, Iva ; Džanić, Emir ; Alajbeg, Ivan NAVS Naphthalan for Treatment of Oral Mucosal Diseases – A Pilot Study // Acta Dermatovenerologica Croatica, 4 (2014), 22; 250-258

Podaci o odgovornosti

Andabak Rogulj, Ana ; Brkić, Denis ; Alajbeg, Iva ; Džanić, Emir ; Alajbeg, Ivan

engleski

NAVS Naphthalan for Treatment of Oral Mucosal Diseases – A Pilot Study

“Non-Aromatic Very rich in Steranes” (NAVS) naphthalan isva purified natural oil derivative, abundant in steranes (geogenic „steroids“). The purpose of this study was to evaluate the effectiveness of NAVS in the treatment of oral lichen planus (OLP) and recurrent aphthous stomatitis (RAS). We used NAVS oil in adhesive paste in 11 patients with clinically and histologically proven OLP (open label), and in 7 patients with RAS (double blind randomized ; topical betamethasone in adhesive paste used as control). The severity of the OLP lesions was objectively scored. The number and diameter of RAS lesions were assessed on days 0, 3, and 5. The intensity of pain and discomfort was determined using visual analogue scale (VAS) and „Oral health impact profile“ (OHIP-14) before and after therapy. OLP cumulative activity scores on days 0 and 28 were 101.5 and 48.5, respectively (t=5.99 ; P=0.0001). Using NAVS for 28 days resulted in 52.2% overall clinical improvement. Cumulative OHIP-14 scores on days 0 and 28 were 210 and 142, respectively (t=5.65 ; P=0.0002). Out of a total of 7 patients with RAS, 4 of them were treated with NAVS and 3 with topical corticosteroids. There were no statistically significant differences in improvement rate between the two groups (lesion number (day 3 P=0.29 ; day 5 P=0.32) ; lesion diameter (day 3 P=0.64 ; day 5 P=0.74)). NAVS successfully reduced the clinical signs and symptoms of OLP, and reduced the number, diameter, and symptoms in patients with RAS, statistically comparable with corticosteroids.

Naphthalan ; non-aromatic ; therapy ; topical ; lichen planus, oral ; aphthous stomatitis, recurrent ; oral health impact profile ; visual analogue scale

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o izdanju

4 (22)

2014.

250-258

objavljeno

1330-027X

1847-6538

Povezanost rada

Dentalna medicina

Poveznice
Indeksiranost